Quarterly report [Sections 13 or 15(d)]

Segment Information

v3.25.3
Segment Information
9 Months Ended
Sep. 30, 2025
Segment Reporting [Abstract]  
Segment Information

7. Segment Information

 

Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker (“CODM”), in deciding how to allocate resources and in assessing performance. The Company and the Company’s chief operating decision maker view the Company’s operations and manage its business in one operating segment, which is the business of identifying, developing, and commercializing pharmaceutical products for the treatment of medical and aesthetic skin conditions and diseases.

 

The CODM, who is the Chief Executive Officer (“CEO”), President, and Chairman of the Board, manages and allocates resources to the operations of the Company on an entity-wide basis. The Company’s measure of segment profit or loss is net loss. Managing and allocating resources on an entity-wide basis enables the CEO to assess the overall level of resources available and how to best deploy these resources across functions and research and development projects that are in line with the Company’s long-term company-wide strategic goals. Consistent with this decision-making process, the CEO uses financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources, and setting incentive targets. Operating expenses are used to monitor budget versus actual results. The CODM does not review assets in evaluating the results of the Company, and therefore, such information is not presented.

 

 

Given the Company’s September 2025 strategic pivot to prioritize the development and distribution of OTC products, the segment information disclosure has been recast for all periods presented to reflect this change. The following table summarizes the segment’s financial information including the Company’s significant segment expenses:

 

    2025     2024     2025     2024  
   

Three Months Ended

September 30,

   

Nine Months Ended

September 30,

 
    2025     2024     2025     2024  
Research and development                                
Clinical   $ -     $ 1,920,092     $ 705,645     $ 4,359,819  
Chemistry, manufacturing and controls     36,274       127,781       320,104       346,273  
Personnel related     468,113       353,486       1,377,614       1,305,109  
Total research and development     504,387       2,401,359       2,403,363       6,011,201  
Selling, general and administrative                                
Public company compliance     475,503       562,777       1,991,676       2,147,927  
Marketing     472,940       -       472,940       -  
Personnel related     307,841       261,517       1,005,226       1,153,826  
Total selling, general and administrative     1,256,284       824,294       3,469,842       3,301,753  
Interest income     68,682       52,497       176,536       176,431  
Net loss   $ (1,691,989 )   $ (3,173,156 )   $ (5,696,669 )   $ (9,136,523 )